Celgene’s Revlimid flops in Phase III lymphoma study, shares slide
Shares of Celgene were dinged Monday evening after the Big Biotech noted that its top franchise drug Revlimid didn’t make the cut as a maintenance therapy for diffuse large B-cell lymphoma (DLBCL).
While the drug hit the primary endpoint for progression-free survival compared to a placebo in the Phase III REMARC study, investigators at the Lymphoma Academic Research Organization in France say it failed to make a significant difference in overall survival. As a result, Celgene says it’s dropping plans for a regulatory filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.